G. Omar et al., KETOCONAZOLE AND FLUCONAZOLE INHIBITION OF THE METABOLISM OF CYCLOSPORINE-A BY HUMAN LIVER IN-VITRO, Therapeutic drug monitoring, 19(4), 1997, pp. 436-445
The effects of the important antifungal agents, ketoconazole (Ket) and
fluconazole (Flu), on the microsomal metabolism of cyclosporin A (CsA
) by seven human livers was measured in vitro, A total of eight CsA me
tabolites were identified by high-performance liquid chromatography, w
ith metabolites AM9 and AM1 predominating. Ket was a stronger inhibito
r than Flu for the formation of each of the 8 metabolites; the mean IC
50 for the inhibition of total CsA metabolism was 0.26 +/- 0.08 mu M a
nd 85.7 +/- 23.9 mu M for Ket and Flu, respectively. Inhibition by Ket
and Flu was noncompetitive, with Ki = 0.13 mu M and 25.1 mu M, respec
tively. There was considerable interindividual variation in the sensit
ivity of CsA metabolism to inhibition by Ket or Flu and the degree of
inhibition was not uniform across the range of individual CsA metaboli
tes. In six of the seven livers tested, Ket and Flu inhibited the aggr
egate formation of secondary metabolites (AM19, AM49, AM4N9, and AM1c)
more than the aggregate formation of primary metabolites (AM9, AM1, a
nd AM4N) and inhibited the formation of AM9 more than AM1. Although th
e degree of inhibition of total CsA metabolism by Flu correlated direc
tly with the control (uninhibited) rate of total CsA metabolism (r = 0
.95), no similar correlation for inhibition by Ket was noted, nor was
the magnitude of inhibition by Ket and Flu related. The results are di
scussed in relation to the inhibition of CsA metabolism by Ket and Flu
in patients in vivo and to the possibility of changes in the efficacy
and toxicity of CsA as a result of alterations in its metabolite prof
ile.